Clinical Study Sponsored by TaxolCur, LL

PacCur® is a novel patented cancer medicine with proven active agents that are combined in a nanoformulation administered intravenously during a short 15-30 minute infusion in the veterinarian’s clinic. An open INAD (Investigational New Animal Drug) is guiding the studies for safety, efficacy and drug manufacturing to FDA standards. In preliminary studies presented to FDA, dogs have been safely administered the drug on a weekly basis, with improved tolerability over other formulations of these drugs. PacCur, Inc. is actively seeking partners to further this research and obtain clinical approval of this drug in this first indication. As we progress with success, the drug is expected to work in several other important canine cancers including breast, lung, ovarian and prostate.

For more company-related information you may reach out to us


Midwestern University Animal Health Institute is located in new state-of the-art research and clinical laboratories in North Central Phoenix, AZ andis where patients will be treated under IACUC-approved protocols.